How doctors providing oral cancer medications affects patients with advanced prostate cancer
Official title: Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients
Funded at University of Michigan at Ann Arbor · NIH-11240115 · Data updated 2026-11-12
This study is looking at how giving advanced prostate cancer patients their medications directly from their doctors' offices can make it easier for them to get and stick to their treatments, while also checking if this approach helps improve their health outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | February 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $400,622 |
| NIH project number | 7R01CA275993-04 |
| Project ID | NIH-11240115 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer who are prescribed oral specialty drugs.
✕Less likely to help
Patients with early-stage prostate cancer or those not receiving oral specialty drugs may not benefit from this research.
What this research studies
This research investigates the impact of physicians dispensing oral specialty drugs directly to patients with advanced prostate cancer. By allowing urologists and oncologists to provide medications in their offices, the study aims to improve patient access and adherence to treatments like abiraterone and enzalutamide. The research will explore both the benefits of this delivery model and the potential financial incentives that may influence prescribing practices. Ultimately, it seeks to understand how these changes affect patient outcomes and treatment efficacy.
Why it matters
Potential benefit: If successful, this research could enhance the way advanced prostate cancer is treated, leading to better patient access to effective medications and improved health outcomes.
How similar studies have gone: Previous research has shown that similar approaches to medication delivery can improve patient adherence and outcomes, suggesting potential success for this study.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Hollenbeck, Brent K. — University of Michigan at Ann Arbor
- Study coordinator: Hollenbeck, Brent K.
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.